Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor-β1 in Autosomal Dominant Polycystic Kidney Disease Patients
Corresponding Author
Derya Kocer
Department of Biochemistry, Training and Research Hospital, Kayseri, Turkey
Address correspondence and reprint requests to Derya Kocer, Department of Biochemistry, Kayseri Training and Research Hospital, Kayseri 38010, Turkey. E-mail: [email protected]Search for more papers by this authorCigdem Karakukcu
Department of Biochemistry, Training and Research Hospital, Kayseri, Turkey
Search for more papers by this authorFahir Ozturk
Department of Internal Medicine, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorEray Eroglu
Department of Internal Medicine, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorIsmail Kocyigit
Department of Nephrology, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorCorresponding Author
Derya Kocer
Department of Biochemistry, Training and Research Hospital, Kayseri, Turkey
Address correspondence and reprint requests to Derya Kocer, Department of Biochemistry, Kayseri Training and Research Hospital, Kayseri 38010, Turkey. E-mail: [email protected]Search for more papers by this authorCigdem Karakukcu
Department of Biochemistry, Training and Research Hospital, Kayseri, Turkey
Search for more papers by this authorFahir Ozturk
Department of Internal Medicine, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorEray Eroglu
Department of Internal Medicine, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorIsmail Kocyigit
Department of Nephrology, Erciyes University Medical Faculty, Kayseri, Turkey
Search for more papers by this authorAbstract
Renal interstitial fibrosis is an important pathological feature of autosomal dominant polycystic kidney disease (ADPKD), which progressively develops to end-stage renal disease (ESRD). It has been shown that apelin and transforming growth factor-β1 (TGF-β1) play important roles in the renal fibrosis process. The aim of the present study is to evaluate the relationship of these fibrosis markers and ADPKD. Forty-five patients with ADPKD and 28 healthy controls were studied cross-sectionally. Estimated glomerular filtration rate (eGFR), apelin, TGF-β1 were measured in all participants, using conventional methods. Apelin levels were lower (1.2 ± 0.9 ng/mL vs. 2.5 ± 1.3 ng/mL, P < 0.001), while TGF-β1 levels were higher in the patient group according to healthy controls (466.5 ± 200.5 ng/L vs. 367.1 ± 163.45 ng/L, P = 0.031), respectively. Apelin was negatively correlated with TGF-β1 and highly sensitive C-reactive protein (hs-CRP); and positively correlated with eGFR. In all subjects, eGFR was independently predicted by TGF-β1 and apelin. Apelin and TGF-β1 may be used as biomarkers of renal fibrosis that is an important pathological feature of ADPKD, which progressively develops to ESRD in ADPKD patients.
References
- 1Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777–784.
- 2Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332–342.
- 3Grantham JJ. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: Recent advances. Am J Kidney Dis 1996; 28: 788–803.
- 4Border W, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286–1292.
- 5Choi ME, Ding Y, Kim SI. TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol 2012; 32: 244–252.
- 6Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. Nephron Clin Pract 2012; 121: 91–94.
- 7Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198–211.
- 8Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–71.
- 9Dray C, Knauf C, Daviaud D et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008; 8: 437–445.
- 10Reaux A, De Mota N, Skultetyova I et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001; 77: 1085–1096.
- 11Sato T, Suzuki T, Watanabe H et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 2013; 123: 5203–5211.
- 12Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes 2013; 62: 1970–1980.
- 13Chen H, Li J, Jiao L et al. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol 2014; 592: 505–521.
- 14Wang LY, Diao ZL, Zhang DL et al. The regulatory peptide apelin: a novel inhibitor of renal interstitial fibrosis. Amino Acids 2014; 46: 2693–2704.
- 15Pchejetski D, Foussal C, Alfarano C et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 2012; 33: 2360–2369.
- 16Melgar-Lesmes P, Casals G, Pauta M et al. Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 2010; 151: 5306–5314.
- 17El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010; 70: 421–427.
- 18Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7–13.
- 19Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. Lancet 1994; 343: 824–827.
- 20Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Int Med 2009; 150: 604–612.
- 21Hus-Citharel A, Bouby N, Frugiere A, Bodineau L, Gasc JM, Llorens-Cortes C. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int 2008; 74: 486–494.
- 22Lacquaniti A, Chirico V, Lupica R et al. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Peptides 2013; 49: 1–8.
- 23Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in adpkd in rats. Kidney Int 2001; 60: 2087–2096.
- 24Kocyigit I, Kaya MG, Orscelik O et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 2012; 36: 11–18.
- 25Kocyigit I, Eroglu E, Orscelik O et al. Pentraxin3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. J Nephrol 2014; 27: 181–186.
- 26Leeper NJ, Tedesco MM, Kojima Y et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009; 296: 1329–1335.
- 27Codognotto M, Piccoli A, Zaninotto M et al. Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am J Nephrol 2007; 27: 1–6.
- 28Aoki J, Ikari Y, Nakajima H et al. Clinical and pathological characteristics of dilated cardiomyopathy in haemodialysis patients. Kidney Int 2005; 67: 333–340.
- 29O'Shea M, Hansen MJ, Tatemoto K, Morris MJ. Inhibitory effect of apelin-12 on nocturnal food intake in the rat. Nutr Neurosci 2003; 6: 163–167.
- 30Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1–12.
- 31Chen H, Wan D, Wang L et al. Apelin protects against acute renal injury by inhibiting TGF-β1. Biochim Biophys Acta 2015; 1852: 1278–1287.
- 32Helal I, McFann K, Reed B et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 380–385.
- 33Han M, Park HC, Kim H et al. Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 2014; 15: 63.
- 34Kocyigit I, Yilmaz MI, Orscelik O et al. Serum Uric Acid Levels and Endothelial Dysfunction in Patients with Autosomal Dominant Polycystic Kidney Disease. Nephron Clin Pract 2013; 123: 157–164.
Citing Literature
